The ROE as of December 2024 (TTM) for Syndax Pharmaceuticals, Inc. (SNDX) is -64.34%

According to Syndax Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -64.34%. This represents a change of 287.44% compared to the average of -16.61% of the last 4 quarters.

Syndax Pharmaceuticals, Inc. (SNDX) Historical ROE (quarterly & annually)

How has SNDX ROE performed in the past?

The mean historical ROE of Syndax Pharmaceuticals, Inc. over the last ten years is -20.83%. The current -64.34% ROE has changed 208.86% with respect to the historical average. Over the past ten years (40 quarters), SNDX's ROE was at its highest in in the March 2015 quarter at 85.92%. The ROE was at its lowest in in the December 2019 quarter at -44.30%.

Syndax Pharmaceuticals, Inc. (SNDX) ROE by Quarter and Year

Discovering the peaks and valleys of Syndax Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Syndax Pharmaceuticals, Inc. (SNDX) Average ROE

How has SNDX ROE performed in the past?

The current ROE of Syndax Pharmaceuticals, Inc. (SNDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Syndax Pharmaceuticals, Inc. (SNDX) ROE vs. Peers

How is SNDX’s ROE compared to its peers?

Syndax Pharmaceuticals, Inc.’s ROE is greater than Cogent Biosciences, Inc. (-70.85%), greater than Cullinan Oncology, Inc. (-26.54%), greater than KalVista Pharmaceuticals, Inc. (-103.92%), greater than Mersana Therapeutics, Inc. (-401.37%), greater than Pliant Therapeutics, Inc. (-48.91%), greater than Revolution Medicines, Inc. (-33.67%), greater than Viridian Therapeutics, Inc. (-45.47%), greater than Inozyme Pharma, Inc. (-88.42%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Replimune Group, Inc. (-53.12%), greater than Vaxcyte, Inc. (-23.53%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Merus N.V. (-45.38%), greater than Sutro Biopharma, Inc. (-97.01%), less than Cytokinetics, Incorporated (335.19%), less than DICE Therapeutics, Inc. (56.07%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Karuna Therapeutics, Inc. (-25.23%), greater than Dyne Therapeutics, Inc. (-57.46%),

Build a custom stock screener for Syndax Pharmaceuticals, Inc. (SNDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Syndax Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Syndax Pharmaceuticals, Inc. (SNDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Syndax Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.